AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Precision Neuroscience Corporation has closed an oversubscribed $250 million Series D funding round led by Pershing Square Inc. and the Ackman Oxman Institute, among others, to advance its brain-computer interface technology.
PRIVATESep 24, 2026
Amount Raised
$250 Million
Round Type
Series D
New YorkHealth Care
Investors
Jsl Health CapitalHitachi VenturesKorea Investment PartnersMirae Asset CapitalMubadala CapitalInvusArk InvestB CapitalDuquesne Family OfficeAckman Oxman InstitutePershing Square Inc.
Description
Precision Neuroscience Corporation has announced the successful closure of a $250 million Series D financing round. The funding was co-led by Pershing Square Inc. and the Ackman Oxman Institute, reflecting the strong interest in brain-computer interface technology. The company has raised a total of $430 million since its inception in 2021
Company Information
Company
Precision Neuroscience
Location
54 W. 21st St.
New York, New York, United States
About
Precision Neuroscience is working to provide breakthrough treatments for the millions of people worldwide suffering from neurological illnesses. The company is building the only brain–computer interface designed to be minimally invasive, safely removable, and capable of processing large amounts of data.
Fundz sees it the moment Precision Neuroscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkHealth Care